Janssen's Sirukumab Faces Difficult US Commercial Path Even If It Clears Approval Hurdles

FDA advisory committee's concerns about a mortality imbalance in Plivensia clinical trials would appear to reduce the odds that the interleukin-6 inhibitor will reach the US market in the near term.